David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.
David I. Quinn, MBBS, PhD
Advertisement
Articles by David I. Quinn, MBBS, PhD
Advertisement
Latest Updated Articles
Dr. Quinn on Targetable Molecular Pathways in RCCPublished: March 26th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5